IL-13-LCL-SIM monotherapy induced an upregulation in the expression of VEGF (Figures 4, 5A,C; Table 4), presumably secreted by tumor cells as a compensatory mechanism for direct targeting of pro-angiogenic macrophages by IL-13-conjugated liposomes (Li et al., 2016). This evidence concerns the gene IL13 and neoplasm.